Fluidigm Co. (NASDAQ:FLDM) Director Samuel D. Colella Buys 9,000 Shares of Stock

Fluidigm Co. (NASDAQ:FLDM) Director Samuel D. Colella acquired 9,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was purchased at an average cost of $7.00 per share, with a total value of $63,000.00. Following the completion of the acquisition, the director now directly owns 115,481 shares of the company’s stock, valued at approximately $808,367. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ:FLDM opened at $6.98 on Friday. The stock has a 50-day simple moving average of $10.99. The company has a current ratio of 3.26, a quick ratio of 2.86 and a debt-to-equity ratio of 0.30. Fluidigm Co. has a 12-month low of $6.57 and a 12-month high of $14.90. The firm has a market cap of $477.62 million, a price-to-earnings ratio of -8.73 and a beta of 2.15.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, August 1st. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.08). Fluidigm had a negative return on equity of 38.30% and a negative net margin of 57.48%. The business had revenue of $28.20 million during the quarter, compared to analyst estimates of $30.16 million. Fluidigm’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, equities analysts predict that Fluidigm Co. will post -0.55 earnings per share for the current year.

Several equities research analysts recently weighed in on the company. Piper Jaffray Companies increased their price target on Fluidigm from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Zacks Investment Research raised Fluidigm from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Wednesday, July 3rd. ValuEngine downgraded Fluidigm from a “buy” rating to a “hold” rating in a report on Wednesday, June 12th. Finally, BidaskClub raised Fluidigm from a “sell” rating to a “hold” rating in a report on Friday, July 19th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $14.75.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FLDM. FMR LLC acquired a new position in shares of Fluidigm in the 1st quarter valued at about $24,188,000. ClariVest Asset Management LLC acquired a new position in shares of Fluidigm in the 1st quarter valued at about $8,154,000. Allianz Asset Management GmbH lifted its stake in shares of Fluidigm by 146.6% in the 2nd quarter. Allianz Asset Management GmbH now owns 1,030,722 shares of the medical research company’s stock valued at $12,698,000 after purchasing an additional 612,774 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Fluidigm by 171.1% in the 4th quarter. Millennium Management LLC now owns 932,996 shares of the medical research company’s stock valued at $8,042,000 after purchasing an additional 588,862 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Fluidigm in the 2nd quarter valued at about $5,360,000. 93.25% of the stock is currently owned by institutional investors and hedge funds.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Featured Story: Google Finance Portfolio Tips and Tricks

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.